Cauda equina neuroendocrine tumor

Last revised by Rohit Sharma on 20 Jan 2024

Cauda equina neuroendocrine tumors are rare sporadic WHO grade 1 tumors, almost invariably found below the conus arising either from the filum terminal or less commonly from the cauda equina 5

These tumors were previously known as spinal paragangliomas however they are molecularly and genetically distinct from paragangliomas seen elsewhere in the body and as such the term neuroendocrine tumor is preferred 5.

The age range at presentation for spinal paragangliomas varies from childhood to older age (9-75 years of age) with most cases being diagnosed in middle age (30-60 years) 5. Males are somewhat more commonly affected than females 1-5.

Unlike paragangliomas/pheochromocytomas that are commonly encountered as part of inherited syndromes, cauda equina neuroendocrine tumors are almost always sporadic 5

The clinical presentation is either with local mass effect or neuroendocrine symptoms. 

The most common presenting symptoms are lower back pain and sciatica from mass effect.

Cauda equina neuroendocrine tumor frequently actively secrete neuropeptides, particularly 5-hydroxytryptamine and somatostatin, although symptoms related to this chemical production are usually absent. 

Additionally, these lesions may be a rare source of superficial siderosis, and thus present with sensory neural impairment, cranial nerve dysfunction and myelopathy 4.

Paragangliomas of the spine usually arise in the region of the cauda equina, although rare reports of lesions elsewhere along the spine are available. They are indolent and considered WHO grade 1 tumors in the 5th edition (2021) WHO classification of CNS tumors 5

Cauda equina neuroendocrine tumors are highly vascular masses, the majority (75%) of paragangliomas are encapsulated, usually attached to the filum terminale or less commonly a nerve root 5

All paragangliomas consist of two types of cells; type I and type II. The main components are lobules or nests of chief cells (type I); these structures are known as Zellballen. They are surrounded by a single layer of sustentacular cells (type II) 5.

Immunohistochemical examination confirms neuroendocrine differentiation of chief cells (type I) 5

Sustentacular cells (type II):

  • S100: usually positive

  • GFAP: usually positive

Numerous mutations have been identified as predisposing to paragangliomas including VHL, RET, NF1, SDHAF2, SDHB, SDHC, SDHD, TNEM127 and MAX 5

Plain films are unlikely to demonstrate any abnormality, although vertebral scalloping or rarely calcification may be seen 4

Spinal paragangliomas appear as soft tissue masses inferior to the conus. If contrast is administered they enhance vividly (as do paragangliomas elsewhere). 

Large lesions may rarely demonstrate osseous erosion or remodeling of the adjacent vertebrae (vertebral scalloping). Rarely, these lesions calcify 4.

Conventional angiography demonstrates an intense early blush that persists into the late arterial and early venous phases.

Similarly, on MRI these masses usually appear as well-circumscribed masses, inferior to the conus. 

With some lesions, the characteristic salt-and-pepper appearance of neck and skull base paragangliomas may also be seen. Associated syringohydromyelia has been reported in some cases.

Reported signal characteristics include:

  • T1: isointense

  • T2

    • hyperintense

    • flow voids are typically seen along the surface of and within the tumor nodule

    • hemorrhage is common, leading to a hemosiderin cap sign

  • T1 C+ (Gd): intense enhancement is virtually always seen

Surgical resection is the treatment of choice, sometimes with preoperative embolization to reduce intra-operative blood loss. Resection alone is usually curative with a post-resection recurrence rate of less than 5% 1-5.

Rarely CSF dissemination is encountered 5

The differential diagnosis is essentially that of other intradural extramedullary tumors, particularly those located in the lumbar region. 

ADVERTISEMENT: Supporters see fewer/no ads